| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from continuing operations | -4,822,060 | -3,392,305 |
| Loss from discontinued operations, net of tax | - | 0 |
| Stock-based compensation | 499,078 | 309,152 |
| Depreciation and amortization of intangible assets | 62,404 | 46,136 |
| Amortization of right of use assets | 114,553 | 93,174 |
| Loss on forward purchase agreement | - | 0 |
| Change in fair value of earnout liabilities | -56,474 | 29,630 |
| Inventory write-down | 47,082 | - |
| Accounts receivable and other current assets | -34,129 | -26,155 |
| Inventory | -334,394 | -222,210 |
| Prepaid expenses | -408,517 | -321,096 |
| Accounts payable | -196,966 | 258,791 |
| Accrued expenses and other liabilities | 670,346 | 592,530 |
| Amortization of debt discount | - | 0 |
| Lease liability | -117,902 | -95,712 |
| Net cash used in operating activities | -3,022,899 | -1,589,143 |
| Cash paid for offering costs | - | 15,000 |
| Cash paid for elevai acquisition transaction costs | 150,000 | 150,000 |
| Purchases of property and equipment | 14,224 | - |
| Proceeds from issuance of loans | - | 0 |
| Net cash used in investing activities | -164,224 | -165,000 |
| Proceeds from issuance of common stock, net of costs | 3,483,790 | 3,397,476 |
| Proceeds from exercise of common stock warrants | 1,000,000 | - |
| Repayment of loans | 344,578 | 249,273 |
| Net cash provided by financing activities | 4,139,212 | 3,148,203 |
| Net increase (decrease) in cash | 952,089 | 1,394,060 |
| Cash and cash equivalents at beginning of period | 157,139 | - |
| Cash and cash equivalents at end of period | 1,109,228 | - |
Longevity Health Holdings, Inc. (XAGE)
Longevity Health Holdings, Inc. (XAGE)